Response to Critique of the Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) Trial by Abou-Chebl and Steinmetz

摘要: See related article, p 2682. Even before the early results of Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) trial were published,1 commentaries that critical or attempted to explain poor outcome patients treated with stenting published being submitted publication.2–4 Subsequent publication SAMMPRIS results, other soon followed.5–12 As lead investigators SAMMPRIS, we welcome scientific debate on possible limitations implications management intracranial stenosis design future trials this high-risk disease. However, these opinions should be based an accurate representation data from trial. The recent critique by Abou Chebl Steinmetz12 fails regard. Their contains inaccurate references study protocol, incorrect derivations event rates trial, selective use unpublished presented at a meeting. These used support authors' viewpoint, whereas same presentation contradicted viewpoint omitted. The purpose article is correct deficiencies errors Abou-Chebl Steinmetz. ### Incorrect References In their critique, Steinmetz claim relationships between specific lesion procedural variables periprocedural complications misrepresented primary New England Journal Medicine ( NEJM ). They write “Although authors vessel size was not risk complications, there greater ICH (10% versus 0%) if prestent diameter …